JP2021155415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021155415A5 JP2021155415A5 JP2021049350A JP2021049350A JP2021155415A5 JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5 JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fluorobenzyl
- pyridin
- oxy
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025083688A JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000787P | 2020-03-27 | 2020-03-27 | |
| US63/000787 | 2020-03-27 | ||
| US202063126113P | 2020-12-16 | 2020-12-16 | |
| US63/126113 | 2020-12-16 | ||
| US202163135870P | 2021-01-11 | 2021-01-11 | |
| US63/135870 | 2021-01-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Division JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021155415A JP2021155415A (ja) | 2021-10-07 |
| JP2021155415A5 true JP2021155415A5 (https=) | 2024-03-21 |
Family
ID=75252595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049350A Ceased JP2021155415A (ja) | 2020-03-27 | 2021-03-24 | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230201185A1 (https=) |
| EP (2) | EP4537816A3 (https=) |
| JP (2) | JP2021155415A (https=) |
| KR (1) | KR20220157486A (https=) |
| CN (1) | CN115348863A (https=) |
| AU (1) | AU2021244918A1 (https=) |
| BR (1) | BR112022017578A2 (https=) |
| CA (1) | CA3176569A1 (https=) |
| ES (1) | ES3031577T3 (https=) |
| IL (1) | IL296694A (https=) |
| MX (1) | MX2022010811A (https=) |
| TW (1) | TWI823072B (https=) |
| WO (1) | WO2021191812A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250214968A1 (en) * | 2022-03-25 | 2025-07-03 | Ildong Pharmaceutical Co., Ltd. | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof |
| CN119585249A (zh) * | 2022-07-22 | 2025-03-07 | 辉瑞公司 | 用于制备2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟基甲基)丙-2-胺盐的方法及中间体 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN116675680B (zh) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | 一种氘代化合物及其制备方法、药物和应用 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025224648A1 (en) * | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025252098A1 (zh) * | 2024-06-05 | 2025-12-11 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的口服药物组合物及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU2001296000A1 (en) * | 2000-10-24 | 2002-05-27 | Ajinomoto Co., Inc. | Nateglinide-containing hydrophilic drug preparations |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TWI538748B (zh) * | 2011-11-16 | 2016-06-21 | 鴻海精密工業股份有限公司 | 鏡頭除塵裝置 |
| WO2013117963A1 (en) * | 2012-02-09 | 2013-08-15 | Piramal Enterprises Limited | Stable oral tablet dosage form of an antidiabetic compound |
| EP3091981B1 (en) * | 2014-01-09 | 2021-03-10 | Verastem, Inc. | Compositions and methods for treatment of abnormal cell growth |
| JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| BR112018069782A2 (pt) * | 2016-03-31 | 2019-01-29 | Lupin Ltd | composição farmacêutica de dapagliflozina |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
-
2021
- 2021-03-24 JP JP2021049350A patent/JP2021155415A/ja not_active Ceased
- 2021-03-24 ES ES21714685T patent/ES3031577T3/es active Active
- 2021-03-24 BR BR112022017578A patent/BR112022017578A2/pt not_active Application Discontinuation
- 2021-03-24 CA CA3176569A patent/CA3176569A1/en active Pending
- 2021-03-24 KR KR1020227036905A patent/KR20220157486A/ko not_active Withdrawn
- 2021-03-24 CN CN202180024485.6A patent/CN115348863A/zh active Pending
- 2021-03-24 MX MX2022010811A patent/MX2022010811A/es unknown
- 2021-03-24 EP EP24223164.5A patent/EP4537816A3/en active Pending
- 2021-03-24 EP EP21714685.1A patent/EP4125896B1/en active Active
- 2021-03-24 IL IL296694A patent/IL296694A/en unknown
- 2021-03-24 WO PCT/IB2021/052430 patent/WO2021191812A1/en not_active Ceased
- 2021-03-24 AU AU2021244918A patent/AU2021244918A1/en not_active Abandoned
- 2021-03-24 TW TW110110639A patent/TWI823072B/zh not_active IP Right Cessation
- 2021-03-24 US US17/906,651 patent/US20230201185A1/en not_active Abandoned
-
2025
- 2025-05-20 JP JP2025083688A patent/JP2025118943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155415A5 (https=) | ||
| JP2021512117A5 (https=) | ||
| MX2022010811A (es) | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| IL275982B2 (en) | Pharmaceutical compositions for treating cystic fibrosis | |
| HRP20250257T1 (hr) | Farmaceutska kombinacija, pripravak i kombinirana priprema koja sadrži aktivator glukokinaze i inhibitor sglt-2 te metode pripreme i njihova uporaba | |
| JP2008515905A5 (https=) | ||
| JP6068765B2 (ja) | 薬学的複合製剤 | |
| WO2004030700A1 (ja) | 固形製剤 | |
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むｐＨ依存性薬物放出特性が改善した剤形 | |
| JP2023536667A5 (https=) | ||
| JP2023532223A5 (https=) | ||
| JP2022537685A5 (https=) | ||
| CN103800336A (zh) | 一种具有抗血栓活性药物的组合物 | |
| CN101766611B (zh) | 一种左旋氨氯地平或其可药用盐和β受体阻滞剂的药物组合物及其应用 | |
| CN102058591A (zh) | 一种左旋氨氯地平和替米沙坦的复方制剂 | |
| WO2010009619A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| KR101497354B1 (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| JP7695724B2 (ja) | 医薬組成物およびその適用 | |
| JP2016505628A (ja) | ２−アミノエタンスルホン酸との組み合わせ | |
| JP2024503689A5 (https=) | ||
| CN101785781B (zh) | 一种左旋氨氯地平或其可药用盐和黑木耳多糖的药物组合物及其应用 | |
| KR20090107960A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| KR20190107838A (ko) | 이바브라딘의 서방성 약제학적 조성물 및 이의 제조방법 |